

Resource Summary Report

Generated by [kravitz2](#) on Aug 10, 2026

Goat anti-Syrian Hamster IgG (H+L) Secondary Antibody, HRP

RRID:AB_10985385

Type: Antibody

Proper Citation

(Thermo Fisher Scientific Cat# PA1-29626, RRID:AB_10985385)

Antibody Information

URL: http://antibodyregistry.org/AB_10985385

Proper Citation: (Thermo Fisher Scientific Cat# PA1-29626, RRID:AB_10985385)

Target Antigen: Syrian Hamster IgG (H+L)

Host Organism: goat

Clonality: polyclonal secondary

Comments: Applications: ELISA, IHC, WB

Antibody Name: Goat anti-Syrian Hamster IgG (H+L) Secondary Antibody, HRP

Description: This polyclonal secondary targets Syrian Hamster IgG (H+L)

Target Organism: hamster

Antibody ID: AB_10985385

Vendor: Thermo Fisher Scientific

Catalog Number: PA1-29626

Record Creation Time: 20250719T080919+0000

Record Last Update: 20260225T224833+0000

Ratings and Alerts

No rating or validation information has been found for Goat anti-Syrian Hamster IgG (H+L) Secondary Antibody, HRP.

No alerts have been found for Goat anti-Syrian Hamster IgG (H+L) Secondary Antibody, HRP.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Pierre Bikorimana J, et al. (2025) A Spike-Accum bioconjugate protein vaccine confers potent SARS-CoV-2-specific immunity. iScience, 28(9), 113314.

Lillehoj EP, et al. (2024) Stenotrophomonas maltophilia provokes NEU1-mediated release of a flagellin-binding decoy receptor that protects against lethal infection. iScience, 27(9), 110866.

Offersgaard A, et al. (2023) An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. iScience, 26(2), 105949.

Shang Y, et al. (2022) Modulation of interleukin-36 based inflammatory feedback loop through the hepatocyte-derived IL-36R-P2X7R axis improves steatosis in alcoholic steatohepatitis. British journal of pharmacology, 179(17), 4378.

Hoagland DA, et al. (2021) Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. Immunity, 54(3), 557.

Fagan-Solis KD, et al. (2020) A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. Cell reports, 30(5), 1385.